+ All Categories
Home > Economy & Finance > Emerging markets: opportunities in health sciences

Emerging markets: opportunities in health sciences

Date post: 01-Dec-2014
Category:
Upload: ey
View: 551 times
Download: 5 times
Share this document with a friend
Description:
Discuss opportunities and issues for health science companies poised to take advantage of the transitional and dynamic landscape across emerging markets.
39
22nd Annual Health Sciences Tax Conference Road map to emerging markets: spotting opportunities and issues in health sciences December 5, 2012
Transcript
Page 1: Emerging markets: opportunities in health sciences

22nd Annual Health Sciences Tax Conference Road map to emerging markets: spotting opportunities and issues in health sciences December 5, 2012

Page 2: Emerging markets: opportunities in health sciences

Road map to emerging markets: spotting opportunities and issues in health sciences

Page 2

Disclaimer

► Any US tax advice contained herein was not intended or written to be used, and cannot be used, for the purpose of avoiding penalties that may be imposed under the Internal Revenue Code or applicable state or local tax law provisions.

Page 3: Emerging markets: opportunities in health sciences

Road map to emerging markets: spotting opportunities and issues in health sciences

Page 3

Disclaimer

Ernst & Young refers to the global organization of member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young LLP is a client-serving member firm of Ernst & Young Global Limited operating in the US. For more information about our organization, please visit www.ey.com. This presentation is © 2012 Ernst & Young LLP. All rights reserved. No part of this document may be reproduced, transmitted or otherwise distributed in any form or by any means, electronic or mechanical, including by photocopying, facsimile transmission, recording, rekeying, or using any information storage and retrieval system, without written permission from Ernst & Young LLP. Any reproduction, transmission or distribution of this form or any of the material herein is prohibited and is in violation of US and international law. Ernst & Young LLP expressly disclaims any liability in connection with use of this presentation or its contents by any third party. Views expressed in this presentation are not necessarily those of Ernst & Young LLP.

Page 4: Emerging markets: opportunities in health sciences

Road map to emerging markets: spotting opportunities and issues in health sciences

Page 4

Panelists

► Chris Finnerty Ernst & Young LLP New York, NY

+1 212 773 7479 [email protected]

► Frank de Meijer Ernst & Young Terco São Paulo, Brazil

+55 11 2573 3413 [email protected]

► Ana Mingramm Ernst & Young LLP New York, NY +1 212 773 9190 [email protected]

► Tejas Mody Ernst & Young LLP New York, NY +1 212 773 4496 [email protected]

► Haroon Cheema Director and International Tax Counsel

Merck & Co., Inc. Whitehouse Station, NJ

Page 5: Emerging markets: opportunities in health sciences

Road map to emerging markets: spotting opportunities and issues in health sciences

Page 5

Agenda

► Emerging-markets overview

► Major emerging-markets tax trends: ► Transfer pricing (TP) under increased scrutiny ► Anti-avoidance challenges ► Tax administration and practice tightened

► Mergers and acquisitions

► Other regional developments and opportunities

Page 6: Emerging markets: opportunities in health sciences

Emerging-markets overview

Page 7: Emerging markets: opportunities in health sciences

Road map to emerging markets: spotting opportunities and issues in health sciences

Page 7

Pharmaceutical sales in emerging-markets Pharmaceutical sales in developed markets

Source: IMS Health, July 2012 *Compound annual growth rate (CAGR)

0

50

100

150

200

250

300

350

400

450

2007 2008 2013F 2020F

Sales

(US$

b)

Brazil Russia India China Mexico Turkey Korea

0

100

200

300

400

500

600

2006 2020F

Sales

(US$

b) EU 5 US

CAGR: 15.6%

CAGR: 11.2%

CAGR: 2.00%

Emerging-markets overview — faster growth than developed markets

Page 8: Emerging markets: opportunities in health sciences

Road map to emerging markets: spotting opportunities and issues in health sciences

Page 8

► Eli Lilly & Co.: emerging market revenue falls 4%

► Pfizer Inc.: scales back emerging-markets growth estimates

► Ernst & Young LLP: predicts $47 billion shortfall between forecasted sales and achievable sales for “Big Pharma”

► Emerging market growth drivers: ► Local competition for products and staff ► Construction of factories to facilitate sales approvals ► Pharmaceutical policy changes

Tax considerations are becoming increasingly more important for life sciences companies doing business in the emerging-markets.

Emerging-markets overview — struggles ahead?

Source: Wall Street Journal, August 20, 2012

Page 9: Emerging markets: opportunities in health sciences

Road map to emerging markets: spotting opportunities and issues in health sciences

Page 9

Tightened enforcement

Continuous change

Alignment with international practices

Regular tax inspections

Increased disclosures Tax reform

changes

Tax scrutiny of non-residents

More sophisticated

Expanded jurisdictions

4

1

3 2

►Taxpayers’ information gathering and exchange

►Tax internal control and tax risk profiling

►Strengthening of tax administration and collection

►Various transaction disclosure forms

►Limitation of benefits/anti-treaty shopping clauses in tax treaties ►Changes to tax administration and collection

►Evolving guidance ►Renegotiated tax treaties

►Tax residency

►Transfer pricing audits

►Specific anti-avoidance rules ►General anti-

avoidance/substance over form

►Beneficial ownership

►Permanent establishment

►Transfer pricing practices ►Advance pricing agreements ►Exchange of information

agreements ►Tax-free reorganizations ► International Financial

Reporting Standards

Emerging-markets overview — evolving tax landscape

Page 10: Emerging markets: opportunities in health sciences

Major emerging-markets tax trends — transfer pricing under increased scrutiny

Page 11: Emerging markets: opportunities in health sciences

Road map to emerging markets: spotting opportunities and issues in health sciences

Page 11

Major emerging-markets tax trends — transfer pricing, Asia-Pacific India ► Increasingly aggressive transfer pricing enforcement ► Key industry issues in recent transfer pricing audits concerning:

► Need to satisfy benefits test for management fee payout ► Basis of royalty determination; legal vs economic ownership ► Clinical data management, construed high end, 27% to 30% markup ► Clinical trial coordination, construed high-end research and

development, 22% to 25% markup ► Import prices of active pharmaceutical ingredients (APIs)/finished

dosage formulations (FDFs) ► Comparable uncontrolled price of generics deployed in audits

► Advertising, marketing and promotion expenses ► Compensation for marketing intangible in India

Page 12: Emerging markets: opportunities in health sciences

Road map to emerging markets: spotting opportunities and issues in health sciences

Page 12

Major emerging-markets tax trends — transfer pricing, Asia-Pacific ► Recent legislative changes to transfer pricing provisions:

► Scope of term international transaction enhanced; meaning of term intangible property clarified

► Transfer pricing made applicable to specified domestic transactions

► Procedural and penalty provisions tightened ► Recent introduction of advance pricing agreement (APA) rules

into India law: ► Alternate route to domestic appellate process ► Provision for unilateral, bilateral or multilateral APAs

Page 13: Emerging markets: opportunities in health sciences

Road map to emerging markets: spotting opportunities and issues in health sciences

Page 13

China ► Rapid growth in transfer pricing audit resources at the local

state tax bureau and State Administration of Taxation (SAT) headquarters level

► Stricter TP enforcement according to Guoshuihan [2011] Circular 167

► Industry focus on automotive, consumer products, pharmaceuticals, real estate, hospitality and logistics

► Marketing intangibles and location savings key audit issues ► Three-pronged approach to enforcement:

► Administration: change from investigation afterwards to precaution beforehand ► Service: actively promote APAs and mutual agreement procedures ► Investigation: deepen investigation and enhance intensity (industry focus)

Major emerging-markets tax trends — transfer pricing, Asia-Pacific

Page 14: Emerging markets: opportunities in health sciences

Road map to emerging markets: spotting opportunities and issues in health sciences

Page 14

► Increasing use in the region: mainland China, Singapore, Japan, South Korea, Taiwan, Indonesia, Hong Kong and India.

► APAs can provide certainty for significant investment decisions,

tax structuring and host location analysis.

Taxpayer benefit Tax authority benefit

Certainty of outcome Certainty of tax base

Bilateral/multilateral solution — elimination of risk of double tax

Knowledge-sharing from bilateral/multilateral negotiations

Avoidance of costly, protracted audits More detailed understanding of taxpayer

Dedication of more TP technical resources by tax authorities

Alternative approach to TP enforcement

Major emerging-markets tax trends — transfer pricing, Asia-Pacific APAs

Page 15: Emerging markets: opportunities in health sciences

Road map to emerging markets: spotting opportunities and issues in health sciences

Page 15

Major emerging-markets tax trends — transfer pricing, Latin America Brazil ► Published on April 4, 2012; effective as of 2013 with the option

to be applied for 2012 ► Minimum requirement for the application of the Brazilian

uncontrolled price method (PIC) ► The minimum statutory gross profit margin required when

applying the resale price method (PRL) for the import of goods, services or rights; ranges from 20%–40% depending on the industry

► Freight-on-board price as basis for the PRL calculation ► Changes to the deductibility of interest

Page 16: Emerging markets: opportunities in health sciences

Major emerging-markets tax trends — anti-avoidance challenges

Page 17: Emerging markets: opportunities in health sciences

Road map to emerging markets: spotting opportunities and issues in health sciences

Page 17

► Australia, China, Hong Kong, New Zealand and Singapore have general anti-avoidance rules (GAAR) currently; India is on the way.

► India, Indonesia, Japan and South Korea do not have GAAR provisions but rely on targeted anti-abuse rules/specific anti-abuse rules, substance-over-form and other measures, e.g., Limitation of Benefits (LOB)/anti-abuse provisions in tax treaties to prevent treaty shopping.

► Tax authorities are focusing more on thin capitalization, transfer pricing and treaty shopping (beneficial ownership).

► Permanent establishment as well as tax residency are increasingly audit issues.

► Disclosures, documentation and administrative burdens are increasing steadily in the region.

Major emerging-markets tax trends — anti-avoidance rules, Asia-Pacific

Page 18: Emerging markets: opportunities in health sciences

Road map to emerging markets: spotting opportunities and issues in health sciences

Page 18

Major emerging-markets tax trends — anti-avoidance rules, Asia-Pacific India ► GAAR introduced to counter aggressive tax planning; effective

April 1, 2013 ► Deferral to April 1, 2016 recommended

► GAAR triggered if main purpose or one of the main purposes is to obtain tax benefit and a tainted element is present

► Tainted elements test arm’s-length character, misuse or abuse of law, commercial substance or bonafides of arrangement

► Wide powers to tax authority to disregard or re-characterize arrangement if GAAR invoked

► Expert Committee (EC) constituted by Prime Minister: release of draft report (ECR) containing guidelines for implementation

► Provisions likely to be watered down

Page 19: Emerging markets: opportunities in health sciences

Road map to emerging markets: spotting opportunities and issues in health sciences

Page 19

Major emerging-markets tax trends — anti-avoidance rules, Latin America

Brazil ► New interpretations from the taxpayers’ council in Brazil

► Superior Tribunal de Justica interpretation on payment for imported services; no withholding tax on treaty countries

Mexico ► Tax authorities criteria and recent case law Peru ► New GAAR (effective July 19, 2012) Colombia

► Proposed anti-evasion rules

General trend to adopt substance-over-form approach and require business purpose:

Page 20: Emerging markets: opportunities in health sciences

Major emerging-markets tax trends — anti-avoidance rules, indirect share transfers

Page 21: Emerging markets: opportunities in health sciences

Road map to emerging markets: spotting opportunities and issues in health sciences

Page 21

Major emerging-markets tax trends — indirect share transfers, Asia-Pacific Australia ► Greater than 50% real estate test applies. China ► Circular 698: GAAR can be asserted to disregard

intermediaries and recast as a direct equity transfer. India ► Transfer of shares of foreign company deriving value

substantially from India will be taxed in India as law currently stands; many issues remain.

► EC recently released draft report of key recommendations. Indonesia ► Specific indirect transfer rule targets the use of special-

purpose vehicles domiciled in tax havens.

Page 22: Emerging markets: opportunities in health sciences

Road map to emerging markets: spotting opportunities and issues in health sciences

Page 22

Major emerging-markets tax trends — indirect share transfers, Asia-Pacific

Hong Kong, Malaysia, New Zealand, Singapore

► Nonresidents not taxed on capital gains.

Cambodia, Japan, South Korea, Philippines, Thailand, Vietnam ► Indirect share transfers currently not taxed.

Page 23: Emerging markets: opportunities in health sciences

Road map to emerging markets: spotting opportunities and issues in health sciences

Page 23

Major emerging-markets tax trends — indirect share transfers, Latin America Mexico ► 50% real estate test

Chile ► New rules effective as of January 1, 2013

Peru ► Subject to tax if Peru represents 50% of the value of the

shares transferred

Panama ► Applicable over Panamanian source income only

Page 24: Emerging markets: opportunities in health sciences

Major emerging-markets tax trends — tax administration and practice tightened

Page 25: Emerging markets: opportunities in health sciences

Road map to emerging markets: spotting opportunities and issues in health sciences

Page 25

Major emerging-markets tax trends — tax administration and practice tightened

► Significant activity in tax audits throughout the region

► Generally aggressive audits and large assessments

► Cross-border transactions and transfer pricing

► Pre-controversy management: ► Need to maintain adequate supporting documentation ► Severe penalties and fines imposed by countries in certain countries ► Need for active involvement at the discovery level

► Exchange of information agreements

Page 26: Emerging markets: opportunities in health sciences

Mergers and acquisitions

Page 27: Emerging markets: opportunities in health sciences

Road map to emerging markets: spotting opportunities and issues in health sciences

Page 27

Mergers and acquisitions — Latin America

► Investments and acquisitions ► Made through favorable jurisdictions (Netherlands, Spain, Switzerland) ► Leverage strategies available in most jurisdictions ► Goodwill amortization variable among countries (Brazil, Chile)

► Divestments and exit planning ► Capital gains tax on sale of shares:

► Book value possible in limited countries ► Use of tax treaties to limit capital gains tax

► Reorganizations ► Mergers usually tax free ► Tax free spin-offs (de-mergers) generally possible with few exemptions

(Venezuela, Central America, Uruguay) ► Holding period requirement

► Mexico, Argentina, Peru and proposed changes in Colombia

Page 28: Emerging markets: opportunities in health sciences

Road map to emerging markets: spotting opportunities and issues in health sciences

Page 28

Merger

Slump sale

Itemized sale

Business reorganizations Acquisitions

Mergers and acquisitions

Demerger Asset purchase Share purchase

► Planning inbound structure:

► Comply with Indian regulations/laws

► Structured through tax-efficient jurisdictions

► Hybrid financing possible but requires structuring

► Tax diligence necessary

► Generally tax neutral subject to conditions

► Indian acquiring vehicle can be a corporate or a limited liability partnership

► Possible to claim goodwill amortization

► Sell side tax costs and transaction costs to be analyzed

Mergers and acquisitions — Asia-Pacific, India

Page 29: Emerging markets: opportunities in health sciences

Other regional developments and opportunities — Latin America

Page 30: Emerging markets: opportunities in health sciences

Road map to emerging markets: spotting opportunities and issues in health sciences

Page 30

Other regional developments and opportunities — Latin America

► Significant tax reforms throughout the region ► Argentina

► Significant changes to foreign-exchange controls ► Proposed tax reform for 2013

► Chile ► Tax reform enacted in 2012

► Peru ► Tax reform enacted in 2012

► Colombia ► Proposed tax reform for 2013

► Active increase in tax treaties throughout the region

Page 31: Emerging markets: opportunities in health sciences

Road map to emerging markets: spotting opportunities and issues in health sciences

Page 31

Other regional developments and opportunities — Latin America

► Shared service centers and management fees ► Reduction of withholding taxes

► TreatyCo with Panama Branch ► Use of foreign tax credits

► Shared service centers in Mexico or Brazil

► Supply chain opportunities ► Expanding treaty network ► Free trade zones in the region

Page 32: Emerging markets: opportunities in health sciences

Road map to emerging markets: spotting opportunities and issues in health sciences

Page 32

Other regional developments and opportunities — Brazil indirect taxes (ICMS) ► Senate Resolution 13 introduced ► By 2013, Interstate ICMS value added tax (VAT) rate at 4% for

imported goods ► 2012 rate at 7% or 12% ► Reason: use of import state incentives avoided ► Result:

► Huge buildup of ICMS credits in Brazil ► Use of incentives less attractive ► Rising tax costs

► New supply chain planning needed ► Same rules applicable to locally manufactured goods by 2020

Page 33: Emerging markets: opportunities in health sciences

Road map to emerging markets: spotting opportunities and issues in health sciences

Page 33

Other regional developments and opportunities — Brazil localization for medical equipment

► High demand for medical equipment in Brazil ► Customs duties low; no local production yet ► Initiatives for local production begun ► High financing costs for users ► Alternative: use of Finame for locally produced equipment ► Bidding process of public hospitals: locally manufactured

equipment preferred even when cost margin is higher (up to 25%)

Page 34: Emerging markets: opportunities in health sciences

Road map to emerging markets: spotting opportunities and issues in health sciences

Page 34

► Low factory price ► Basis for manufacturing taxes:

► Single turn-over tax (PIS/Cofins) ► Advanced ICMS (ST)

► High commercial price ► Manufacturing taxes no longer due

Consumer

Distributor

Factory

Create own distribution center to save on turn-over tax (PIS/Cofins) and substitute state VAT (ICMS)

Other regional developments and opportunities — Brazil indirect tax distribution planning

Page 35: Emerging markets: opportunities in health sciences

Road map to emerging markets: spotting opportunities and issues in health sciences

Page 35

Other regional developments and opportunities — future trends in trade Blocs

► Mercosul, CAN and others ► Trend towards protectionism in recent years

► Mercosur maximum external tariff to 35%

► Mercosur trade Bloc appearing continually weaker: ► Fractious relationships between the parties ► Impact on Venezuela’s admission

► Mercosur opposed to entering FTA relationships with US ► US looking for more bilateral agreements ► Mercosur not successful:

► Little growth in export trade between the member states ► Disputes between Argentina and Brazil

► Economic momentum of both Mercosur and CAN slowed ► Truly integrated South America Trade area unlikely in next

5 to 10 years

Page 36: Emerging markets: opportunities in health sciences

Other regional developments and opportunities — Asia-Pacific

Page 37: Emerging markets: opportunities in health sciences

Road map to emerging markets: spotting opportunities and issues in health sciences

Page 37

Other regional developments and opportunities — indirect taxes, India ► Paradigm shift in taxation of services: all services taxable

except negative/exempt list ► Exemption to export services based on newly introduced place-

of-provision-of-services rules ► Seeming impact on technical testing/clinical trial services

► Cumbersome refund process for exporters of goods and services

► Import prices of APIs/FDFs subject to investigation by special valuation branch of India’s Central Board of Excise and Customs

Page 38: Emerging markets: opportunities in health sciences

Road map to emerging markets: spotting opportunities and issues in health sciences

Page 38

Other regional developments and opportunities — indirect taxes, China

► Pilot locations: Shanghai,

Beijing, Anhui, Jiangsu, Fujian, Guangdong (includes Shēnzhèn), Tianjin and Hubei

► Pilot services:

► Transport service ► Certain modern

services industries

► Applicable rates: 17%,11%, 6% and 3%, depending on different classes of VAT payers of the VAT pilot service

► VAT pilot locations and covered industries

Region Launch date

Shanghai January 1, 2012

Beijing September 1, 2012

Anhui and Jiangsu October 1, 2012

Fujian and Guangdong (includes Shēnzhèn)

November 1, 2012

Tianjin, Zhejiang and Hubei

December 1, 2012

Page 39: Emerging markets: opportunities in health sciences

Road map to emerging markets: spotting opportunities and issues in health sciences

Page 39

Questions?


Recommended